Item 16. FORM 10-K SUMMARY

5K characters. Original on sec.gov · Markdown

Item 16. FORM 10-K SUMMARY

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, Abbott Laboratories has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


			ABBOTT LABORATORIES

			By			/s/ ROBERT B. FORD
						Robert B. Ford
						Chairman of the Board and Chief Executive Officer

			Date:			February 16, 2024

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of Abbott Laboratories on February 16, 2024 in the capacities indicated below.


/s/ ROBERT B. FORD						/s/ PHILIP P. BOUDREAU
Robert B. Ford						Philip P. Boudreau
Chairman of the Board and Chief Executive Officer, and Director of Abbott Laboratories (principal executive officer)						Senior Vice President, Finance and Chief Financial Officer (principal financial officer)

/s/ JOHN A. MCCOY, JR.
John A. McCoy, Jr.
Vice President, Finance and Controller (principal accounting officer)

/s/ ROBERT J. ALPERN						/s/ CLAIRE BABINEAUX-FONTENOT
Robert J. Alpern, M.D.						Claire Babineaux-Fontenot
Director of Abbott Laboratories						Director of Abbott Laboratories

/s/ SALLY E. BLOUNT						/s/ PAOLA GONZALEZ
Sally E. Blount, Ph.D.						Paola Gonzalez
Director of Abbott Laboratories						Director of Abbott Laboratories

/s/ MICHELLE A. KUMBIER						/s/ DARREN W. MCDEW
Michelle A. Kumbier						Darren W. McDew
Director of Abbott Laboratories						Director of Abbott Laboratories

/s/ NANCY MCKINSTRY						/s/ MICHAEL G. O'GRADY
Nancy McKinstry						Michael G. O'Grady
Director of Abbott Laboratories						Director of Abbott Laboratories

/s/ MICHAEL F. ROMAN						/s/ DANIEL J. STARKS
Michael F. Roman						Daniel J. Starks
Director of Abbott Laboratories						Director of Abbott Laboratories

/s/ JOHN G. STRATTON
John G. Stratton
Director of Abbott Laboratories

ABBOTT LABORATORIES AND SUBSIDIARIES

SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS

FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021

(in millions)


Allowances for Doubtful Accounts and Product Returns	Balance at Beginning of Year		Provisions/ Charges to Income		Amounts Charged Off and Other Deductions		Balance at End of Year
2023	$	500	$	60	$	(116)	$	444
2022	519		122		(141)		500
2021	460		145		(86)		519

Report of Independent Registered Public Accounting Firm

To the Shareholders and the Board of Directors of Abbott Laboratories

We have audited the consolidated financial statements of Abbott Laboratories and subsidiaries (the Company) as of December 31, 2023 and 2022, for each of the three years in the period ended December 31, 2023, and have issued our report thereon dated February 16, 2024 (included elsewhere in this Annual Report on Form 10-K). Our audits of the consolidated financial statements included the financial statement schedule listed in Item 15(a)(2) of this Annual Report on Form 10-K (the “schedule”). This schedule is the responsibility of the Company's management. Our responsibility is to express an opinion on the Company’s schedule, based on our audits.

In our opinion, the schedule presents fairly, in all material respects, the information set forth therein when considered in conjunction with the consolidated financial statements.

/s/ Ernst & Young LLP

Chicago, Illinois

February 16, 2024

Previous: Item 15. EXHIBIT AND FINANCIAL STATEMENT SCHEDULES